Silence Therapeutics PLC Update on AIM Delisting (6292T)
26 Noviembre 2021 - 1:00AM
UK Regulatory
TIDMSLN
RNS Number : 6292T
Silence Therapeutics PLC
26 November 2021
Silence Therapeutics plc: Update on AIM Delisting
26 November 2021
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN
("Silence" or "the Company"), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today provides a further update
with respect to the cancellation of admission of its ordinary
shares of nominal value GBP0.05 each (the "Ordinary Shares") to
trading on AIM (the "AIM Delisting"), as originally announced on 15
October 2021.
As previously announced, the last day of trading of the
Company's Ordinary Shares on AIM will be 29 November 2021 and the
proposed AIM Delisting will be effective from 7.00 a.m. (London
time) on 30 November 2021. Silence will retain the listing of its
American Depositary Shares, each representing three Ordinary Shares
(the "ADSs"), on the Nasdaq Global Market ("Nasdaq") under the
ticker symbol SLN. Following the AIM Delisting, the Company's ADSs
will remain listed, and will only be tradeable, on Nasdaq.
Information about the process to deposit Ordinary Shares for
delivery of ADSs was provided in the announcement and circular
published by the Company on 15 October 2021 and is also available
on the Company's website at
www.silence-therapeutics.com/investors/AIM-Delisting.
Following the AIM Delisting, Investec Bank plc will cease to act
as nominated adviser and broker to the Company.
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR & Corporate Communications
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European PR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Angela Gray/Chris Welsh
silencetherapeutics@consilium-comms.com
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary mRNAi GOLD(TM) platform can be
used to create siRNAs that precisely target and silence
disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address iron
loading anemias. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Hansoh Pharma, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFEEFDIEFSESF
(END) Dow Jones Newswires
November 26, 2021 02:00 ET (07:00 GMT)
Silence Therapeutics (LSE:SLN)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Silence Therapeutics (LSE:SLN)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
